The relationships between low grade inflammation, demographic and clinical characteristics in patients with OCD

Amaç: Son yıllarda inflamasyonun obsesif kompulsif bozuklukluğun (OKB) etyolojisindeki rolüne ilişkin kanıtlar artmaktadır. Bildiğimiz kadarıyla, OKB'li olgularda C-reaktif protein (CRP) ile klinik ve demografik özellikleri arasındaki ilişkiyi araştırmış herhangi bir çalışma yoktur. Bu çalışmada OKB'li olgularda CRP düzeyleri ile psikopatolojik ve demografik değişkenler arasındaki ilişkiyi değerlendirmeyi amaçladık. Yöntem: OKB tanısı konmuş ardışık 98 ayaktan hasta ayrıntılı olarak değerlendirildi. Inflamasyon göstergesi olarak değerlendirme sırasında bakılan CRP sonuçları hastaların bilgisayar kayıtlarından araştırıldı. Rutin olarak bakılan tetkiklerinde CRP kesme değeri 3 mg/dl olarak kabul edilerek (>=3 olan hastalar yüksek CRP;

OKB hastalarında düşük dereceli inflamasyonla klinik ve sosyodemografik özelliklerin ilişkisi

Objective: To our knowledge, no study has specifically examined the relationship between C-reactive protein CRP levels and clinical features in patients with obsessive compulsive disorder (OCD), even though inflammation plays a role in the etiology of OCD. The aim of this study was to assess the associations between CRP levels and psychopathological and demographic variables in OCD. Methods: Ninety-eight consecutive outpatients with a diagnosis of OCD underwent a detailed clinical assessment for OCD. The study also utilized a cross-sectional patients' records design for obtaining CRP levels. Two groups of patients were compared by CRP levels at the cutoff of 3 mg/dl (high vs. normal). Results: Patients with high CRP levels exhibited worse insight, had earlier age of illness onset, higher rates of previous suicide attempts and positive family history for OCD compared to subjects with normal CRP levels. The logistic regression included three predictive variables for CRP status in patients with OCD (a) YBOCS-insight scores (b) age at onset and (c) family history of OCD. Conclusion: Our data indicates a significant association between inflammation and some clinical features in OCD. Future studies should prospectively examine longitudinal changes in CRP and its' association with clinical and demographic features.

___

  • 1. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010; 15:53-63.
  • 2. Fontenelle LF, Barbosa IG, Luna JV, de Sousa LP, Abreu MN, Teixeira AL. A cytokine study of adult patients with obsessive-compulsive disorder. Compr Psychiatry 2012; 53(6):797-804.
  • 3. Denys D, Fluitman S, Kavelaars A, Heijnen C, Westenberg H. Decreased TNF-alpha and NK activity in obsessive-compulsive disorder. Psychoneuroendocrinology 2004; 29(7):945-952.
  • 4. Brambilla F, Perna G, Bellodi L, Arancio C, Bertani A, Perini G, et al. Plasma interleukin-1?and tumor necrosis factor concentrations in obsessive compulsive disorders. Biol Psychiatry 1997; 42(11):976-981.
  • 5. Ravindran AV, Griffiths J, Merali Z, Anisman H. Circulating lymphocyte subsets in obsessive compulsive disorder, major depression and normal controls. J Affect Disord 1999; 52:1-10.
  • 6. Morgado P, Freitas D, Bessa JM, Sousa N, Cerqueira JJ. Perceived stress in obsessivecompulsive disorder is related with obsessive but not compulsive symptoms. Front Psychiatry 2013; 4(21):1-6.
  • 7. Konuk N, Tekin IO, Ozturk U, Atik L, Atasoy N, Bektas S, et al. Plasma levels of tumor necrosis factor-alpha and interleukin-6 in obsessive compulsive disorder. Mediators Inflamm 2007; 2007:65704.
  • 8. Deodhar SD. C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med 1989; 56(2):126-130.
  • 9. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999; 7(2):169-177.
  • 10. Abraham J, Campbell CY, Cheema A, Gluckman TJ, Blumenthal RS, Danyi P. C-reactive protein in cardiovascular risk assessment: a review of the evidence. J Cardiometab Syndr 2007; 2:119-123.
  • 11. Barzilay R, Lobel T, Krivoy A, Shlosberg D, Weizman A, Katz N. Elevated C-reactive protein levels in schizophrenia inpatients is associated with aggressive behavior. Eur Psychiatry 2016; 31:8-12.
  • 12. Penninx BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S, et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition Study. Biol Psychiatry 2003; 54:566-572.
  • 13. De Berardis D, Campanella D, Gambi F, La Rovere R, Carano A, Conti CM, et al. The role of C-reactive protein in mood disorders. Int J Immunopathol Pharmacol 2006; 19:721-725.
  • 14. Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 2007; 149:267-271.
  • 15. Khandaker GM. Association between serum Creactive protein and DSM-IV generalized anxiety disorder in adolescence: Findings from the ALSPAC cohort, Neurobiology of Stress (2016), http://dx.doi.org/10.1016/j.ynstr.2016.02.003.
  • 16. Miguel EC, Leckman JF, Rauch S, do RosarioCampos MC, Hounie AG, Mercadante MT, et al. Obsessive-compulsive disorder phenotypes: implications for genetic studies. Mol Psychiatry 2005; 10(3):258-275.
  • 17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth ed., Text Revision (DSM-IV-TR). Washington, DC: APA, 2000.
  • 18. Corapcioglu A, Aydemir O, Yildiz M. Structured clinical interview for DSM-IV (SCID-IV), Turkish Version (Turkish). Ankara: Hekimler Yayın Birliği, 1999.
  • 19. Coskunol H, Bagdiken I, Sorias S. SCID-II (Türkçe versiyonu) görüşmesinin kişilik bozukluklarındaki güvenilirligi. Turk Psikoloji Dergisi 1994; 9:26-29.
  • 20. First MB, Spitzer RL, Gibbon M. Structured clinical interview for DSM-IV Axis I disorders (SCID) Clinician Version. Washington, DC: American Psychiatric Press; 1996.
  • 21. Folstein MF, Folstein SE, McHugh PR. MiniMental State Examination: User's Guide. Odessa, FL: Psychological Assessment Resources, 2001.
  • 22. Goodman WK, Price LH, Rasmussen SA. The Yale-Brown Obsessive-Compulsive Scale I: development, use and reliability. Arch Gen Psychiatry 1989; 46:1006-1011.
  • 23. Tek C, Uluğ B, Rezaki G. Yale-Brown ObsessiveCompulsive Scale and US National Institute of Mental Health Global Obsessive Compulsive Scale in Turkish: reliability and validity. Acta Psychiatrica Scan 1995; 91:410-413.
  • 24. Arumugham SS, Cherian AV, Baruah U, Viswanath B, Narayanaswamy JC, Math SB, et al. Comparison of clinical characteristics of familial and sporadic obsessive-compulsive disorder. Compr Psychiatry 2014; 55(7):1520-1525.
  • 25. Sicras-Mainar A, Rejas-Gutiérrez J, NavarroArtieda R, Blanca-Tamayo M. C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. Eur Psychiatry 2013; 28:161-167.
  • 26. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
  • 27. Matsunaga H, Kiriike N, Matsui T, Oya K, Iwasaki Y, Koshimune K, et al. Obsessive-compulsive disorder with poor insight. Compr Psychiatry 2002; 43:150-157.
  • 28. Catapano F, Perris F, Fabrazzo M, CioffiV, Giacco D, De Santis V, et al. Obsessive-compulsive disorder with poor insight: a three-year prospective study. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:323-330.
  • 29. Aigner M, Zitterl W, Prayer D, Demal U, Bach M, Prayer L, et al. Magnetic resonance imaging in patients with obsessive-compulsive disorder with good versus poor insight. Psychiatry Res 2005; 140:173-179.
  • 30. Closhen D, Bender B, Luhmann HJ, Kuhlmann CR. CRP-induced levels of oxidative stress are higher in brain than aortic endothelial cells. Cytokine 2010; 50:117-120.
  • 31. Brebner K, Hayley S, Zacharko R, Merali Z, Anisman H. Synergistic effects of interleukin-1?, interleukin-6, and tumor necrosis factor-?: central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacol 2000; 22(6):566- 580.
  • 32. Sawada H, Oeda T, Umemura A, Tomita S, Hayashi R, Kohsaka M, et al. Subclinical elevation of plasma C-reactive protein and illusions/hallucination in subjects with Parkinson's disease: case-control study. PLoS One 2014; 9(1):858- 886.
  • 33. Pauls DL, Alsobrook II JP, Goodman W, Rasmussen S, Leckman JF. A family study of obsessivecompulsive disorder. Am J Psychiatry 1995; 152(1):76-84.
  • 34. Grabe HJ, Ruhrmann S, Ettelt S, Buhtz F, Hochrein A, SchulzeRauschenbach S, et al. Familiality of obsessive-compulsive disorder in nonclinical and clinical subjects. Am J Psychiatry 2006; 163(11):1986-1992.
  • 35. Chabane N, Delorme R, Millet B, Mouren M-C, Leboyer M, Pauls D. Early-onset obsessivecompulsive disorder: a subgroup with a specific clinical and familial pattern? J Child Psychol Psychiatry 2005; 46(8):881-887.
  • 36. Gray SM, Bloch MH. Systematic review of proinflammatory cytokines in obsessive-compulsive disorder. Current Psychiatry Reports 2012; 14(3):220-228.
  • 37. Black C, Miller BJ. Meta-analysis of cytokines and chemokines in suicidality: distinguishing suicidal versus nonsuicidal patients. Biol. Psychiatry 2015; 78(1):28-37.
  • 38. Gibbs HM, Davis L, Han X, Clothier J, Eads LA, Cáceda R. Association between C reactive protein and suicidal behavior in an adult inpatient population. J Psychiatr Res 2016; 79:28-33.
  • 39. Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 2013; 30(4):297-306.
  • 40. Vargas HO, Nunes SO, Pizzo de Castro M, Bortolasci CC, Sabbatini Barbosa D, Kaminami Morimoto H, et al. Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. J Affect Disord 2013; 150(3):923-930.